Evaluation of Two Potent and Selective PET Radioligands to Image COX-1 and COX-2 in Rhesus Monkeys.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29959215.
- Also identified by DOI 10.2967/jnumed.118.211144 and PMC identifier 6278897.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study assessed whether the newly developed PET radioligands <sup>11</sup>C-PS13 and <sup>11</sup>C-MC1 could image constitutive levels of cyclooxygenase (COX)-1 and COX-2, respectively, in rhesus monkeys. <b>Methods:</b> After intravenous injection of either radioligand, 24 whole-body PET scans were performed. To measure enzyme-specific uptake, scans of the 2 radioligands were also performed after administration of a nonradioactive drug preferential for either COX-1 or COX-2. Concurrent venous samples were obtained to measure parent radioligand concentrations. SUVs were calculated from 10 to 90 min. <b>Results:</b><sup>11</sup>C-PS13 showed specific uptake in most organs, including spleen, gastrointestinal tract, kidneys, and brain, which was blocked by COX-1, but not COX-2, preferential inhibitors. Specific uptake of <sup>11</sup>C-MC1 was not observed in any organ except the ovaries and possibly kidneys. <b>Conclusion:</b> The findings suggest that <sup>11</sup>C-PS13 has adequate signal in monkeys to justify its extension to human subjects. In contrast, <sup>11</sup>C-MC1 is unlikely to show significant signal in healthy humans, though it may be able to do so in inflammatory conditions.
Medical subject headings
- Cyclooxygenase 1
- Cyclooxygenase 2
- Positron-Emission Tomography
- Pyrimidines
- Radiopharmaceuticals